Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

Abstract

IntroductionIn Australia, there is an unmet need for improved treatments for rheumatoid arthritis (RA). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. To provide an overview of key study outcomes for tofacitinib in Australian patients, we analyzed the efficacy and safety of tofacitinib in the Australian subpopulation of global RA phase III and long-term extension (LTE) studies.MethodsData were pooled from the Australian subpopulation of four phase III studies and one LTE study (database not locked at cut-off date: January 2016). Patients in the phase III studies received tofacitinib 5 or 10 mg twice daily (BID), placebo (advancing to tofacitinib at months 3 or 6), or adalimumab, with background methotrexate or conventional synthetic disease-modifying antirheumatic drugs. Patients in the LTE study received tofacitinib 5 or 10 mg BID. Efficacy endpoints were American College of Rheumatology (ACR) 20/50/70 response rates, and change from baseline in the Disease Activity Score in 28 joints, erythrocyte sedimentation rate [DAS28-4(ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores. Safety endpoints included incidence of adverse events (AEs), serious AEs, and discontinuations due to AEs. AEs of special interest and laboratory parameters were analyzed in the LTE study.ResultsAcross phase III studies (N = 100), ACR response rates and improvements in DAS28-4(ESR) and HAQ-DI scores were numerically greater with tofacitinib vs. placebo at month 3, and increased until month 12. The results were sustained in the LTE study (N = 99) after 60 months’ observation. In general, the efficacy and safety profiles of tofacitinib were similar to those of the global RA population.ConclusionsIn Australian patients with RA, tofacitinib therapy demonstrated sustained efficacy and consistent safety over ≥ 60 months’ treatment.FundingPfizer Inc.Trial registration numbers (all ClinicalTrials.gov)NCT00960440; NCT00847613; NCT00856544; NCT00853385; NCT00413699.Electronic supplementary materialThe online version of this article (10.1007/s40744-018-0118-2) contains supplementary material, which is available to authorized users.

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

“…Until recently, treatments for moderate‐to‐severe AD were mainly TCS and topical calcineurin inhibitors, with broad systemic immuosuppressants such as ciclosporin, azathioprine or methotrexate . Dupilumab, a subcutaneously administered anti‐IL‐4 receptor α antagonist monoclonal antibody, was approved for AD treatment in 2017 . Baricitinib, a selective JAK1 and JAK2 inhibitor, is the first‐in‐its‐class oral therapy showing significant improvement in AD signs and symptoms in phase III trials in adults with moderate‐to‐severe disease, widening therapeutic choices for this population.…”

Tofacitinib in recalcitrant scleritis: First case report from India

“…Many cytokines are implicated in the pathophysiology of uveitis, many of which are blocked by JAK/STAT inhibitors, including IL 2, IL 4, IL 15, IL 21. [ 2 3 ] This leads us to believe JAK/STAT inhibitors would be effective in cases of uveitis. Besides, tofacitinib is also FDA approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative arthritis, all of which are frequent systemic associations of scleritis suggesting it may be efficacious in resolution of the uveitis component of the disease as well.…”

Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors

“…13 Pan-inhibitors can have various side effects. 14 The pan-JAK inhibitor tofacitinib is found to be associated with anemia and an increased risk of infections, 15 in some human patients, which may be attributed to its ability to induce lymphopenia 16 via JAK2 inhibition. JAK2 homodimers are only involved initially in the signaling pathway of erythropoietin (EPO), a red blood cell growth factor.…”